Search Results
Your search for ,had matches 18483 pages
Showing 10201 - 10250American Cancer Society Updates Colorectal Cancer Screening Guideline
An updated American Cancer Society guideline now says colorectal cancer screening should begin at age 45 for people at average risk, based in part on data showing rates of colorectal cancer are increasing in young and middle-aged populations. The updated recommendations were published by Wolf et al ...
Safety of PD-1/PD-L1 Inhibitors in Patients With NSCLC and Preexisting Autoimmune Disorders
In a study reported in the Journal of Clinical Oncology, Leonardi et al found that programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor monotherapy in patients with non–small cell lung cancer (NSCLC) and autoimmune disorders worsened such disorders in a...
Multiple-Gene Sequencing vs BRCA1/2-Only Testing After Breast Cancer Diagnosis
In a retrospective cohort study reported in JAMA Oncology, Kurian et al found that use of germline multiple-gene sequencing has become more common than BRCA1/2-only sequencing after breast cancer diagnosis in clinical practice, with an associated increased detection of pathologic variants not...
FDA Accepts Supplemental New Drug Application for Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma
On May 29, the U.S. Food and Drug Administration (FDA) accepted for filing the supplemental new drug application (sNDA) for cabozantinib (Cabometyx) tablets as a treatment for patients with previously treated advanced hepatocellular carcinoma (HCC). The filing has been assigned a Prescription Drug...
Former Chair of ASCO’s Health Disparities Committee, Karen M. Winkfield, MD, PhD, Faced Her Own Barriers
Nationally regarded radiation oncologist Karen M. Winkfield, MD, PhD, was born and reared in Wheatley Heights, a suburban hamlet on Long Island, New York, that shares borders with the prosperous community of Dix Hills and one of the Island’s lowest-income towns, Wyandanch. “I was fortunate to live ...
ASCO, ABIM Collaborate on Pathway to Maintenance of Board Certification
ASCO and the American Board of Internal Medicine (ABIM) have announced that they are working to co-create a pathway to provide doctors with a flexible way to maintain board certification. The work with ASCO reflects real progress in ABIM’s efforts to collaborate with medical societies. Beginning in ...
Valued Mentors and a Link Between Science and Medicine Paved the Road to Oncology for Alice Tsang Shaw, MD, PhD
Lung cancer expert Alice Tsang Shaw, MD, PhD, was born and reared in Gaithersburg, a small suburb located to the northwest of Washington, DC. Both her parents were chemists, and during high school, Dr. Shaw had a keen interest in science, particularly biology, yet the thought of pursuing a career...
Education Came First for Breast Cancer Expert Beverly Moy, MD, MPH, Daughter of Chinese Immigrants
Beverly Moy, MD, MPH, grew up in Brooklyn, New York, in a modest working-class home. Both her parents were immigrants from China. “Education is highly prized in Chinese culture, and my home life was no exception. I didn’t speak any English when I began kindergarten, so that was a bit challenging,...
A Love of Science Leads to an Esteemed Career in Cancer Research for Razelle Kurzrock, MD
Razelle Kurzrock, MD, regarded internationally for her work in translational science, was born and reared in Toronto, Canada. “My parents were immigrants from Eastern Europe. My father, who was Jewish, was a Holocaust survivor. My parents put a strong emphasis on education,” she said. ‘The...
FDA Oncology Drug Approvals Granted Between June 2017 and May 16, 2018
Over the past year (June 2017–May 2018), the U.S. Food and Drug Administration (FDA) granted approval to a number of new oncology drug products, including several biosimilar products. Here we provide the labeling approved for these novel drugs and new indications. EPOETIN ALFA-EPBX (RETACRIT)...
A Love of Older Patients With Cancer Drives a Career Path for Arti Hurria, MD, FASCO
Arti Hurria, MD, FASCO, who is Director of City of Hope’s Center for Cancer and Aging, is a first generation of immigrant parents from India. “My parents left India and moved from England to Canarsie, Brooklyn, where I was born. When I was 8, my family moved to Southern California, partly due to...
Pioneer in Genitourinary Oncology, José R. Germà-Lluch, MD, PhD, Sheds Light on Treating Rare Tumors
“At the age of 6, my mother threw me into the arms of Hippocrates’ discipline, giving me as a special gift a toy suitcase full of medical equipment and a little puppet to train my skills with a stethoscope, syringe, thermometer, small reflex hammer, and torch to explore the oropharyngeal airways....
Husband and Wife Leave a Giant Legacy in Oncology
The remarkable careers of Jimmie C. Holland, MD, and James F. Holland, MD, spanned collectively for more than a century, leaving an indelible footprint in oncology clinical care and research. Synonymous with cancer care itself, the Hollands were a living documentary of the rich and dramatic history ...
International Oncologist Nagi S. El Saghir, MD, FACP, Returned Home to Make a Difference in Lebanon and Worldwide
Internationally renowned expert on the early detection, prevention, and treatment of younger women with breast cancer, Nagi S. El Saghir, MD, FACP, FASCO, was born on January 5, 1953, in Bint Jbeil, a village in southern Lebanon. His parents moved to Beirut in 1948, at the height of the...
Pioneering Researcher and Oncologist Volker S. Diehl, MD, Helped Unlock the ‘Black Box’ of Hodgkin Lymphoma
Volker S. Diehl, MD, the internationally renowned hematologist and researcher, was born in Berlin, Germany, on February 28, 1938—arguably one of the most tumultuous periods in world history. Germany had just invaded Austria, signaling the dark intentions of the Third Reich. In 1943, the air raids...
AUA 2018: Is Prostate Cancer Screening and Risk Stratification Moving Beyond the PSA Test?
New diagnostic tests for prostate cancer, as well as new information about the impact of the U.S. Preventive Services Task Force recommendations on prostate cancer screening, were presented at the 113th Annual Meeting of the American Urological Association (AUA). PSA Screening of African American...
AUA 2018: Apalutamide Significantly Reduced Risk of PSA Progression in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
A post-hoc analysis from the phase III SPARTAN study that showed treatment with apalutamide (Erleada) significantly reduced the risk of prostate-specific antigen (PSA) progression in patients with nonmetastatic castration-resistant prostate cancer (CRPC) who had a rapidly rising PSA while receiving ...
AUA 2018: Use of MRI for Prostate Cancer Screening and Management
Use of magnetic resonance imaging (MRI) in the diagnosis of prostate cancer is increasing and brings added value to screening and surveillance, according to new studies presented this year during the 113th Annual Meeting of the American Urological Association (AUA). Four studies highlighting the...
AUA 2018: Panel Discusses New Research on Prostate Cancer Management Protocols and Treatments
Researchers presented new findings on a Korean Food and Drug Administration (KFDA)-approved robotic system, safety of testosterone therapy after prostate cancer, and active surveillance protocol for low-risk prostate cancer patients at the 113th Annual Meeting of the American Urological Association ...
Risk-Prediction Tool Helps Tailor Lung Cancer Screening to Patient Preference and Clinical Benefit
A microsimulation model study found that the benefits of low-dose computed tomography (CT) screening for lung cancer varied substantially across the eligible population, with 3 factors being particularly influential: lung cancer risk, competing risks or life expectancy, and patient...
Risk of Recurrence in Stage III Colon Cancer According to RAS- and BRAF-Mutation Status
In a study in the PETACC-8 trial population reported in JAMA Oncology, Julien Taieb, MD, PhD, of the Université Paris Descartes, and colleagues found that the risk of recurrence in patients with stage III colon cancer differed for the primary tumor location according to RAS- and BRAF-mutation...
Number of Metastatic Lymph Nodes and Survival in Hypopharyngeal/Laryngeal Cancer
A study using National Cancer Database data has shown that the number of metastatic nodes is a primary independent factor associated with an increased mortality risk in patients with hypopharyngeal and laryngeal cancers. The study was reported in JAMA Oncology by Allen S. Ho, MD, of the Samuel...
Hormonal Contraception and Breast Cancer Risk
As reported in The New England Journal of Medicine by Lina S. Mørch, PhD, of the University of Copenhagen, and colleagues, a Danish study has shown that the risk of breast cancer is increased in hormonal contraception users vs nonusers, with the absolute increase in risk being small. The study...
Stage IV Lung Cancer Did Not Stop Me From Climbing Mera Peak
A veteran mountain climber and skier, I’ve been healthy for most of my 61 years, so it was especially shocking to experience a bout of shortness of breath during a moderately intense mountain bike ride with my wife, Jan, in the spring of 2014. A never-smoker, I was used to climbing up high mountain ...
Study Finds Mutated Tau May Be a Susceptibility Factor for Cancer
Tau proteins perform the function of stabilizing microtubules, a major element of the eukaryotic cytoskeleton. Traditionally associated with neurodegeneration, tau also has a role in the maintenance of genome stability and chromosome integrity and is tightly linked to the development of cancer. A...
BRAF Mutations, Survival, and Recurrence in Patients Undergoing Surgery for Colorectal Cancer Liver Metastases
In a study reported in JAMA Surgery, Margonis et al found that presence of a BRAF V600E mutation was associated with higher risk of recurrence and poorer overall survival among patients undergoing surgical resection of liver metastases from colorectal cancer. Study Details The cohort study...
Trametinib Treatment for Histiocytic Sarcoma With an Activating MAP2K1 Mutation
In a letter to the editor in The New England Journal of Medicine, Gounder et al described the successful treatment of a patient with histiocytic sarcoma and an activating MAP2K1 (MEK1) mutation with the MAPK kinase 1 and 2 inhibitor trametinib (Mekinist). As noted by the authors, patients with...
High–Nicotine-Dependent Smokers Less Likely to Quit After Lung Cancer Screening
A new study by Rojewski et al in CHEST investigated the relationships between the degree of nicotine dependence and both the likelihood of successfully quitting smoking and clinical outcomes in a cohort of screened patients. The study found that patients with a higher nicotine dependence...
FDA Identifies Efficacy Issue in Clinical Trials of Pembrolizumab or Atezolizumab as Monotherapy in Urothelial Cancer With Low Expression of PD-L1
On May 18, the U.S. Food and Drug Administration (FDA) alerted health-care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of pembrolizumab (Keytruda) or atezolizumab (Tecentriq) as monotherapy in clinical trials to treat patients with ...
For James Allison, PhD, Perseverance and Hard Science Are Paramount in Cancer Research
For this installment in the Living a Full Life series of articles, guest editor Jame Abraham, MD, interviewed immunology pioneer James Allison, PhD, Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research,...
Treating Insomnia in Cancer Survivors
A Patient-Centered Outcomes Research Institute–supported randomized clinical trial of cancer survivors showed that 8 weeks of either acupuncture or cognitive behavioral therapy for insomnia (CBT-I) decreased the severity of insomnia among cancer survivors, though improvements were greatest among...
Closing the Gap in Oncology Care for Adolescents and Young Adults
During her presentation “Adolescent and Young Adult Survivorship: What Do We Still Need to Know?” at the 2017 Cancer Survivorship Symposium: Advancing Care and Research, Emily S. Tonorezos, MD, MPH, a general internist in the Adult Long-Term Follow-Up Program at Memorial Sloan Kettering Cancer...
Molecular Minimal Residual Disease Detection Shows Further Promise in Acute Myeloid Leukemia
Extended next-generation sequencing genomic profiling in acute myeloid leukemia (AML) has revealed remarkable heterogeneity and molecular complexity of the disease and provided critical insights into the genetic mechanisms underpinning of preleukemic and leukemic pathogenesis.1,2 Despite...
Circulating Tumor Cells and Benefit of Adjuvant Radiotherapy in Early Breast Cancer
In a study reported in JAMA Oncology, Goodman et al found that adjuvant radiotherapy was associated with better outcome in patients with early breast cancer who had detectable circulating tumor cells (CTCs). Study Details The analysis included data from patients with stage pT1 to pT2 and pN0 to...
PARP Inhibitor Shows Promise in Patients With BRCA-Mutated Pancreatic Cancer
A targeted therapy that has been effective in fighting ovarian cancer in women, including those with BRCA1 and BRCA2 mutations, may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options. An international team of researchers was...
Targeted Sequencing Detection of Molecular Minimal Residual Disease and Prognosis in Acute Myeloid Leukemia
In a study reported in The New England Journal of Medicine, Mojca Jongen-Lavrencic, MD, PhD, of Erasmus MC Cancer Institute, and colleagues found that molecular minimal residual disease identified by next-generation sequencing during complete remission was associated with an increased risk of...
Once-Weekly vs Every-3-Week Cisplatin Chemoradiation in Locally Advanced Head and Neck Cancer
In an Indian phase III trial reported in the Journal of Clinical Oncology, Vanita Noronha, MD, of Tata Memorial Hospital, Mumbai, and colleagues found that curative-intent adjuvant chemoradiation with cisplatin at 100 mg/m2 every 3 weeks produced better locoregional control vs cisplatin at 30...
How a Recent Study Heats up the Debate Over Intraperitoneal Chemotherapy in Newly Diagnosed Advanced Ovarian Cancer
Based on pharmacokinetic and preclinical data, there appears to be a biologic advantage to the use of intraperitoneal chemotherapy in treating some malignancies confined to the abdomen. Since most ovarian, fallopian tube, and peritoneal cancers present and recur in the peritoneal cavity, this...
The American Society of Clinical Oncology at a Glance
The American Society of Clinical Oncology (ASCO) held its first scientific Annual Meeting on April 9, 1965, in the Bellevue Stratford Hotel in Philadelphia. More than 70 members and invited guests attended the inaugural event, which featured three presentations on leukemia and multiple myeloma. The ...
Adding Hyperthermic Intraperitoneal Chemotherapy to Cytoreductive Surgery Improves Outcomes in Advanced Ovarian Cancer
In a Dutch/Belgian phase III trial reported in The New England Journal of Medicine by Willemien J. van Driel, MD, PhD, of the Netherlands Cancer Institute, and colleagues, the addition of hyperthermic intraperitoneal chemotherapy (aka HIPEC) to interval cytoreductive surgery following neoadjuvant...
A Lifetime of Accomplishments in Oncology Brings Knighthood to Sir Murray F. Brennan, MD, FACS
Sir Murray F. Brennan, MD, FACS, was born on April 2, 1940, in Auckland, New Zealand, which lies on and around an isthmus surrounded by the sparkling azure waters of the Hauraki Gulf. “I was born at the beginning of World War II. Fortunately, my father was too old to be drafted into the army. I...
Nancy L. Bartlett, MD, Moved From Engineering to Medicine After a Stint in the ER
Nationally recognized oncologist Nancy L. Bartlett, MD, had an early love for mathematics and a swooning aversion to the sight of blood. “I was born and reared in Kansas City, Missouri and am a Midwesterner at heart. No one in the family was involved in medicine. My mom was an elementary school...
Monica M. Bertagnolli, MD, FASCO, a Cattle Rancher’s Daughter, Becomes ASCO President
ASCO President-Elect Monica M. Bertagnolli, MD, FASCO, was born and reared in Wyoming, where her family ran a cattle ranch in the foothills of the snow-topped peaks of the Wind River Range (or “Winds” for short), a place of breathtakingly uncluttered vistas where the chief feature is the air...
Role of MRI in Detection of Clinically Significant Prostate Cancer: ‘Practice-Affirming’ Results From The PRECISION Trial
Simultaneously presented at the 2018 European Association of Urology meeting and published in The New England Journal of Medicine, the PRECISION trial will go down as a landmark study for solidifying the role of magnetic resonance imaging (MRI) in prostate cancer diagnosis.1 This trial provides...
MRI-Targeted vs Standard Biopsy in Prostate Cancer Diagnosis: The PRECISION Trial
In the international PRECISION trial reported in The New England Journal of Medicine, Veeru Kasivisvanathan, MRCS, of University College London, and colleagues found that magnetic resonance imaging (MRI)-targeted biopsy resulted in a significantly higher rate of diagnosis of clinically significant ...
Brentuximab Vedotin in Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
On March 20, 2018, brentuximab vedotin (Adcetris) was approved for the treatment of adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.1,2 Supporting Efficacy Data Approval was based on the findings of the open-label phase III...
Tisagenlecleucel for Adults With Relapsed or Refractory Large B-Cell Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 1, 2018, tisagenlecleucel (Kymriah), a...
Weighing the Cost and Value of CAR T-Cell Therapy
This past year’s approval by the U.S. Food and Drug Administration (FDA) of two chimeric antigen receptor (CAR) T-cell therapies heralded a new era in both effective cancer treatments and the most expensive cancer drugs ever. Tisagenlecleucel (Kymriah) was initially approved for the treatment of...
FDA Approves Daratumumab/VMP Combination for Newly Diagnosed Multiple Myeloma
On May 7, the U.S. Food and Drug Administration(FDA) approved daratumumab (Darzalex) in combination with bortezomib (Velcade), a proteasome inhibitor; melphalan, an alkylating agent; and prednisone—VMP—for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for...
Ultrahypofractionated Radiotherapy for Prostate Cancer Appears Safe and Effective
Radiotherapy given in high doses over a shorter period of time is safe and effective for patients with prostate cancer, according to research from a phase III trial presented at the European Society for Radiotherapy & Oncology (ESTRO) 37 Conference.1 The treatment—called ultrahypofractionated...
